Kornimate/medical-research-clean huggingface dataset:
ohi--randomized control trial to evaluate efficacy, acceptability, and perception of benefit of an innovative custom afo

Conditions: Accidental Falls; Fall Due to Loss of Equilibrium; High Risk of Falls Due to Mobility Limitation; Diabetes; Arthritis; Cancer; Peripheral Arterial Disease; Parkinson's Disease; End Stage Renal Failure on Dialysis

Summary: the investigators propose a randomized control trial to evaluate long term effects and effectiveness of moore balance brace (mbb) ankle foot orthoses (afo) in reducing risk of falling in older adults. primary endpoints • characterize the impact of mbb afo on balance, gait, risk of falling, frailty status, and adverse events secondary endpoints • characterize the impact of mbb afo on spontaneous daily physical activities • characterize the feasibility of the mbb afo device on patient adherence, acceptability, user-friendliness, and perception of benefit for daily usage


Eligibility criteria:
inclusion criteria: * age 65 or older * high concerns or high risk of fall * ambulatory exclusion criteria: * presence of an active wound infection on either of the foot and ankle * use of medication or a medical condition that may have unstable (fluctuate over time) or temporary (less than one month) impact on gait and balance * acute fractures on the foot * participant of an interventional study within the last 30 days * non-ambulatory or unable to stand without help or walk a distance of at least 1.8 m (\~six feet) without assistance * major foot amputation * unable or unwilling to participate in all procedures

Keywords: ankle foot orthoses falls fall prevention frailty concern for falls footwear mobility
furosemide inhalation in dyspnea of mustard gas exposed patients

Conditions: Bronchiolitis

Summary: to assess the efficacy of inhaled furosemide in mustard gas exposed patients with acute respiratory failure


Eligibility criteria:
inclusion criteria: * patients with a history of exposure to sulfur mustard with a complaint of dyspnea exclusion criteria: * a contraindication for furosemide use; * an accompanying disease in which other drugs effective for dyspnea were used

Keywords: furosemide inhalation dyspnea spirometry mustard gas bronchiolitis sulfur mustard
non enhanced msct in diagnosis of causes of acute abdomen cases

Conditions: Non Enhanced MSCT Abdomen in Diagnosis of Acute Abdomen

Summary: the acute abdomen is one of the most frequent causes for presentation to the emergency department. imaging plays an important role for an accurate diagnosis, which in turn diminishes morbidity and mortality jastaniah and salih demonstrate optimum ct aspects and emphasize on the important features of ct for those patients presenting with an acute abdominal pain at the emergency department. the reported data by this study are based on the author working experience, which forms a continuous protocol adjustment process. the present study provides evidence that ct would result in definite diagnosis of patients with abdominal pain in terms of the detection of some urgent conditions . the acute abdomen may be defined generally as an intra-abdominal process causing severe pain and often requiring medical or surgical intervention. the acute abdomen is a frequent entity at the emergency department, the acute abdomen may be life threatening and so rapid diagnosis of patients presenting with acute abdominal pain is required . diagnostic work-up with imaging can consist of plain x-ray, ultrasonography (us), computed tomography (ct) and even diagnostic laparoscopy. during the last decade, a trend towards increased use of computed tomography in patients with abdominal pain can be seen. in general, acute abdominal pain is responsible for about 10% of total number of patients visiting the emergency. quick and precise diagnosis for the urgent cases is usually vital for treatment. medical imaging is commonly used for the diagnosis of most acute abdomen pain. abdomen and pelvis are reviewed by ct scan. specifically, in cases of acute abdomen complain.

there is no gold standard for diagnosis of acute abdomen as it still a matter of cooperation between clinical data, radiological and laboratory worker. the aim of this study was to demonstrate optimum ct aspects and emphasize on the important features of ct for those patients presenting with an acute abdominal pain clinically suspected to have emergency operation .

Eligibility criteria:
inclusion criteria: * any case of acute abdominal pain suspected to be surgical cases in adults. exclusion criteria: * if pediatric . * if associated with pregnancy. * the patient have severe cardiac or respiratory disease ,cant to lie supine. * if suspected medical case of acute abdomen.
physiological values when breathing in an air-pocket. mountain lab 2019 (ml2019)

Conditions: Accident Caused by Snow Avalanche

Summary: the literature describes and report neurologic intact patients surviving an avalanche several hours after they were buried. the most important factor for surviving more than 15-35 min of burial is considered to be the presence of an air-filled space around the head and neck, termed an air pocket. little is known how the inspired air is influenced by the patients breathing and how oxygen and carbon dioxide diffuse through snow.

in a controlled and simulated avalanche scenario the investigators want to investigate how oxygen (o2) and carbon dioxide (co2) diffuse and how rebreathing of co2 in addition to mild hypoxia influence standardized physiological parameters in two scenarios: fresh air and no fresh air delivered into the air pocket. the project is a field study designed to measure and document gas diffusion through snow. the outcome measures are: (1) concentration of o2 and co2 in the air pocket and 50 cm from the pocket. (2) time interval for development of threshold values for concentration of o2 and co2. the investigators will also monitor physiologic measures such as: electrocardiogram (ecg), continuous invasive blood pressure, cerebral oximetry, continuous pulse oximetry, transthoracic impedance, and gas content in expired air. subjective evaluation of comfort will also be scored. twenty healthy young volunteers with written consent to participate will be used as test subjects. the study may have a clinical consequence for better outcome, for victims of avalanches by providing additional air or oxygen close to the patient. the study will also measure specific body measures and spirometry.

Eligibility criteria:
inclusion criteria: * subject must be healthy * subject must be non smoking * subject must have normal bmi exclusion criteria: * none

Keywords: avalanche, survival, physiology
observational controlled clinical trials, on adult patients with t-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant. evaluation of clinical, anatomy -pathological parameters

Conditions: Lymphoblastic Lymphoma

Summary: the purpose of the study is to create a prospective database of t-lymphoblastic lymphoma (t-lbl) cases in order to conduct an appropriate statistical study as well as to monitor diagnosis and minimal residual disease (mrd), to detect specific genetic profile useful to give advices on therapies, to assess if pet has a prognostic validity on t-lymphoblastic lymphoma (t-lbl).

observational prospective clinical trial designed to: * record all patients treated with a latest generation all-like therapy (e.g.: holzer, lsa2-l2 modified, gimema lal094), an enhanced therapy (hyper-cvad or stanford), autologous or allogeneic transplant or reduced intensity conditioning allotransplant after induction/consolidation and also expected cases treated with high dose sequential therapy or intensified minimal residual disease (mrd) oriented therapy; * enter classic t-lbl patients (bone marrow infiltrate \<25%) treated as long as previous section; * monitor therapy response/phenotype ratio by the study of phenotype; * monitor therapy response/residual disease/patients outcome ratio by the study of t-cell receptor gene rearrangement; * evaluate any gene-profile difference between t-lbl pre-thymic phenotype and t-lbl thymic phenotype so as to correlate it to outcome; * monitor the stage of the disease at diagnosis, during the therapy and during the follow-up by means of tac, so to value if pet (in association with tac) is an additional and/or outcome predicting element compared to tac.

Eligibility criteria:
inclusion criteria: * no previous therapy, except for treatments to face up to clinical presentation of emergency; * medical history initially characterized by nodal mass/masses; * histological and immunophenotypic diagnosis that documents the diagnosis of t-lbl; in cases of bone marrow involvement and difficulties in obtaining nodal material, diagnosis could be based on bone marrow; * availability of biological material for the study of tcr and gene-profile; * age ≥ 15 years; * all stages; * infiltrated bone marrow \<25%; * normal liver, renal and cardiac functions, except for alterations directly related to lymphoma; * estimates of treatment according to one of the last generation schedules; * written informed consent. exclusion criteria: * patients with previous hcv, hbsag+ or suffering from hiv; * patients with organic pathology not related to lymphoma.

Keywords: t-lymphoblastic lymphoma intensive chemo/radiotherapy intensive chemotherapy transplant adult patients
effectiveness study of a behavioral teacher program targeting adhd symptoms

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the goal of this study was to investigate the effectiveness of a behavioral teacher program addressing symptoms of attention-deficit hyperactivity disorder (adhd) in the classroom.

background: most behavioral teacher programs involve intensive and expensive teacher trainings by health care specialists, which may limit successful large-scale implementation. this behavioral program, on the contrary, involves a self-containing manual that does not require expert training in order to increase the likelihood of successful implementation (if proven effective). the aim was to investigate the program's effects on behavioral, socio-emotional and school functioning in primary school children. methods: children with adhd symptoms were randomly assigned at school level to the intervention condition (receiving the program during 18 weeks) or control group (not receiving the program but who were allowed to receive care as usual). measures to assess program's effectiveness: * strengths and weaknesses of adhd-symptoms and normal behavior, * strengths and difficulties questionnaire * social skills rating scale * spence children's anxiety scale * classroom observation code * actigraphy * sociometric measures (peer nomination and peer rating) * dutch arithmetic test (tempo-test-rekenen) * reading test (drie-minuten-toets) and writing test (pi-dictee). additional measures: * wechsler intelligence scale for children (block design and vocabulary; used to estimate iq); * sensitivity to punishment and sensitivity to reward questionnaire and several neuropsychological computer tasks

Eligibility criteria:
inclusion criteria: * sub-threshold or clinical level of adhd symptoms as observed by participant's teacher through the dutch version of the disruptive behavior disorders rating scale (pelham, gnagy, greenslade, \& milich, 1992) * at least one clinical and three sub-threshold adhd symptoms as measured by the teacher telephone interview (holmes et al., 2004), a semi-structured interview which is based on the diagnostic and statistical manual of mental disorders (american psychiatric association, 2000) exclusion criteria: * (medication) treatment for adhd at study entry or in preceding 6 months; * neurological or severe physical condition * iq \< 80 based on a short version of the wechsler intelligence scale for children (block design and vocabulary; legerstee, van der reijden-lakeman, lechner-van der noort, \& ferdinand, 2004; hrabok, brooks, fay-mcclymont, \& sherman, 2014) * participant enrolled in a daily contingency management program or other teacher program targeting behavior or social problems at study entry or in the preceding month * maximum of 2 children per classroom and 5 classrooms per school (in order to limit teachers' burden and increase heterogeneity of teacher and classroom settings)

Keywords: symptoms of adhd
the combination of teriflunomide and danazol for steroid-resistant/relapse immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: to compare the efficacy and safety of teriflunomide plus danazol versus danazol in patients with steroid-resistant/relapse itp

this is a prospective, multicenter, randomized, controlled trial of 124 adult patients with steroid-resistant/relapse itp in china. patients were randomized to receive either experimental teriflunomide plus danazol or active comparator danazol monotherapy. treatment was discontinued if very severe or life-threatening adverse events developed or at the patient's request.

Eligibility criteria:
inclusion criteria: 1. primary immune thrombocytopenia (itp) confirmed by excluding other supervened causes of thrombocytopenia; 2. patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid tapering or after its discontinuation; 3. patients with a platelet count \<30,000/μl or a platelet count \<50,000/μl with bleeding manifestations at the enrollment; 4. willing and able to sign written informed consent. exclusion criteria: 1. secondary immune thrombocytopenia (e.g. patients with hiv, hcv, helicobacter pylori infection, or patients with confirmed autoimmune disease); 2. active or a history of malignancy; 3. pre-existing acute or chronic liver disease, or serum alanine aminotransferase (alt) greater than two times the upper limit of normal (uln); 4. pregnancy or lactation; 5. current or recent (\< 4 weeks prior to screening) clinically serious viral, bacterial, fungal, or parasitic infection; 6. active or chronic viral infection from hepatitis b virus (hbv), hepatitis c virus (hcv), or human immunodeficiency virus (hiv); 7. have evidence of active tuberculosis (tb), or have previously had evidence of active tb and did not receive appropriate and documented treatment, or have had household contact with a person with active tb and did not receive appropriate and documented prophylaxis for tb; 8. have experienced a clinically significant thrombotic event within 24 weeks of screening or are on anticoagulants and in the opinion of the investigator are not well controlled; 9. patients who are deemed unsuitable for the study by the investigator.

Keywords: teriflunomide danazol
human leukocyte antigen (hla) - a*2402 restricted peptide vaccine therapy in patients with advanced gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study it to evaluate the safety and immune response of peptides (urlc10) emulsified with montanide isa51 in treating patients with unresectable, advanced or recurrent gastric cancer.

urlc10 has been identified as cancer specific molecules especially in non small cell lung cancer using genome-wide expression profile analysis by cdna microarray technique. in a prior study, it has been shown that urlc10 are upregulated in esophageal cancer and gastric cancer and other cancer. the investigators identified that peptides derived from these proteins significantly induce the effective tumor specific ctl response in vitro. according to these findings, in this trial, the investigators evaluate the safety, immunological and clinical response of urlc10 peptide vaccine in the patients with gastric cancer. patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. on each vaccination day, the urlc10 peptide (1mg) mixed with montanide isa 51 will be administered by endodermic injection

Eligibility criteria:
inclusion criteria: 1. patients must have advanced or recurrent gastric cancer, and treatment has failed, or in the situation where effective therapy is not available, or has been refused due to severe adverse effects of chemotherapy 2. who performance status of 0 to 2 3. age ≥ 20 years, ≤80 years 4. the patient does not need to have a measurable disease, but must have a disease that an effect judgment is possible 5. passing from previous treatment more than two weeks. 6. expected survival of at least 3 months 7. wbc≥ 1,500/mm³ wbc≤ 15,000/mm³ platelet count ≥ 50,000/mm³ total bilirubin≤ 3 x the institutional normal upper limits ast, alt ≤ 3 x the institutional normal upper limits creatinine ≤ 3 x the institutional normal upper limits 8. patients must be hla-a2402 9. able and willing to give valid written informed consent exclusion criteria: 1. pregnancy, promise of the pregnancy, hope of the pregnancy, breastfeeding 2. serious infections requiring antibiotics 3. concurrent treatment with steroids or immunosuppressing agent 4. decision of unsuitableness by principal investigator or physician-in-charge

Keywords: peptide vaccine urlc10
dose esmolol infusion have an adjuvant effect to tap block for pain control in laparoscopic cholecystectomy.

Conditions: Postoperative Pain

Summary: pain after laparoscopy differs considerably from that seen after laparotomy. laparotomy results mainly in parietal pain (abdominal wall), where as pain in laparoscopy results from stretching of the intra-abdominal cavity, peritoneal inflammation, and diaphragmatic irritation caused by residual carbon-dioxide in the peritoneal cavity. the transverse abdominis plane (tap) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (t6 to l1). while esmolol is an ultra-short acting intravenous β-blocker having a rapid onset and offset effect. it provides an unprecedented level of tolerability and safety in the perioperative setting. when used as an adjunct, it has been shown to improve the postoperative recovery by reducing postoperative pain intensity and intraoperative anesthetic and opioid requirements and preventing opioid-induced hyperalgesia . the mechanism of this synergistic effect is uncertain, but both pharmacokinetic and pharmacodynamics interactions with anesthetic drugs have been proposed.


Eligibility criteria:
inclusion criteria: 1. asa grade i/ii patients undergoing laparoscopic cholecystectomy . 2. age group of 18 -60 years. 3. patients giving valid informed consent. exclusion criteria: 1. patient refusal 2. patients belonging to asa grade iii and grade iv . 3. coagulation disorders. 4. patients with known allergy to one of the used drugs. 5. extreme obesity (bmi \>35) 6. patients with cardiac, pulmonary, hepatic or renal disorders 7. pregnancy 8. drug abusers

Keywords: esmolol infusion tap block cholecystectomy
safety and efficacy of ledipasvir/sofosbuvir (ldv/sof) fixed-dose combination (fdc) for 6 weeks in adults with acute genotype 1 or 4 hepatitis c virus (hcv) and chronic human immunodeficiency virus (hiv)-1 co-infection

Conditions: Hepatitis C Infection With HIV Co-Infection

Summary: the primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (ldv/sof) fixed-dose combination (fdc) in adults with acute genotype 1 or 4 hepatitis c virus (hcv) and chronic human immunodeficiency virus (hiv)-1 co-infection.


Eligibility criteria:
key inclusion criteria: * acute, untreated, hepatitis c infection, genotype 1 or 4, with an estimated duration less than 24 weeks * confirmed hiv-1 infection * cd4 t cell count \>200/μl for individuals receiving antiretroviral therapy (art), cd4 t cell count \> 500/μl at screening for individuals without art * use of two effective contraception methods if female of childbearing potential or sexually active male with female partner key exclusion criteria: * pregnant or nursing female or male with pregnant female partner * chronic liver disease of a non hcv etiology * coinfection with hepatitis b virus (hbv) * treatment with any investigational drug or device within 60 days of the screening visit. * history of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol note: other protocol defined inclusion/exclusion criteria may apply
non-curative esds: assessing the rates and risk factors for residual neoplasia

Conditions: Gastric Neoplasm; Esophageal Neoplasms; Colorectal Neoplasms

Summary: short and long outcomes of esd are well described, particularly in eastern series. however, the outcome of non-curative esds is scarcely reported in the west (particularly among non-gastric or submucosal lesions). therefore, the aim of this project is to describe the european experience with non-curative esds, analysing all the consecutive esds performed in several reference centers, assessing the presence of residual lesion in the endoscopic follow-up or in the surgical specimen.


Eligibility criteria:
inclusion criteria: * all patients submitted to esd due to neoplastic lesions of the gastrointestinal tract exclusion criteria: * patients without endoscopic follow-up or surgery will be excluded from the analysis

Keywords: endoscopic therapy endoscopic submucosal dissection
intravenous versus intraperitoneal instillation of ondansetron for decreasing incidence of nausea and vomiting after laparoscopic gynecological surgeries.

Conditions: Prevention

Summary: study the effect of intraperitoneal instillation vs intravenous ondansetron on ponv added to intraperitoneal bupivacaine for enhanced recovery and to decrease incidence of ponv after laparoscopic surgeries.

laparoscopic surgeries have many advantages e.g., decreasing postoperative pain, better cosmetic, rapid recovery, and better recovery but also, it has side effects e.g., pain, postoperative nausea and vomiting. there are many risk factors that cause ponv either patient related factors or anesthesia related factors (opioids, inhalational anesthetics, nitrous oxide and duration of anesthesia) and surgery related factors (intraabdominal, laparoscopic, postoperative pain). intraperitoneal instillation of drugs can be used for instillation of la, opoids, ketamine and antiemetics to provide analgesia and manage side effects of laparoscopic surgery. the mechanism of action of ondansetron is inhibition of presynaptic 5-ht3 receptors that located in the peripheral nervous. study the effect of intraperitoneal instillation vs intravenous ondansetron on ponv added to intraperitoneal bupivacaine for enhanced recovery and to decrease incidence of ponv after laparoscopic surgeries.

Eligibility criteria:
inclusion criteria: * written informed consent from the patient. * age: 21-60 years old. * female patients * physical status: asa 1\& ii. * bmi = ≤ 35 kg/m2). * type of operation: elective laparoscopic gynecological surgeries. exclusion criteria: * altered mental state. * patients with known history of allergy to the study drugs. * hepatic, renal impairment or disease , cardiovascular, and respiratory diseases. * patients with chronic pain received nsaid or opioid during previous two weeks. * patients with history of ponv or motion sickness and patients received antiemetic therapy 24 h before the surgery.

Keywords: ondansetron intraperitoneal instillation laparoscopic gynecological surgeries postoperative nausea and vomiting